Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Opportunistic Infections

moxifloxacin has been researched along with Opportunistic Infections in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caylá, JA; García-Goez, JF; Miro, JM; Munera, GA; Pacheco, R; Rojas, V1
Alfonso, EC; Almeida, DR; Miller, D1
Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T1
Marchese, A; Roveta, S; Schito, AM; Schito, GC1
Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E1

Other Studies

5 other study(ies) available for moxifloxacin and Opportunistic Infections

ArticleYear
Tuberculosis in recipients of solid-organ transplants during 1995-2015 in Cali, Colombia.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 11-01, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Antitubercular Agents; Colombia; Female; Fluoroquinolones; Graft Rejection; Humans; Male; Middle Aged; Moxifloxacin; Opportunistic Infections; Organ Transplantation; Retrospective Studies; Rifampin; Risk Factors; Sputum; Transplant Recipients; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary; Young Adult

2017
Tsukamurella: an emerging opportunistic ocular pathogen.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2010, Volume: 45, Issue:3

    Topics: Actinomycetales; Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Conjunctivitis, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Gentamicins; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Opportunistic Infections; Quinolines; Tobramycin

2010
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
    Stroke, 2004, Volume: 35, Issue:1

    Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome

2004
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    International journal of antimicrobial agents, 2005, Volume: 26, Issue:5

    Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones

2005
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2001, Volume: 14, Issue:4

    Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins

2001